Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update.

Bisphosphonates (BP),were initially used in industry and later as a drug due to their great affinity to osseous tissue, because of their powerful antiresorptive effect as a treatment in various osteopathies, such as osteoporosis, Paget disease or hypercalcemia associated with some malignant tumors, as myeloma or breast cancer. They are administered orally or intravenously, and although well tolerated, the most frequent side effects are gastrointestinal, in addition to osteonecrosis when they are administered via endovenous. The aim of this work has been to evaluate the existing publications in accredited scientific literature on biphosphonates and their action mechanism and the relationship with the appearance of osteonecrosis of the jaws. Although the mechanism by which osteonecrosis of the jaws develops is not known exactly, there seems to be influence by osteoclast inhibiton, antiangiogenic action, an inhibitory effect on the cellular cycle by the keratinocytes, as well as, reinforcement of the chemiotoxic action in oncological patients treated with other drugs. Clinically, it ranges from a non-specificity of symptoms to lesions such as osteomyelitis with necrosis and osseous sequesters that may be accompanied by fetor ex oris, with the appearance of many Actinomyces contaminated lesions. As for published antecedents on osteonecrosis due to bisphosphonate treatment found until 2006: 46.5% had a previous diagnosis of multiple myeloma; 38.8% were patients with metastatic breast cancer; 6.2% patients of metastatic prostate cancer; 4.1% suffered from osteoporosis; 3.5% from other metastatic diseases and 0.8% had Paget disease. The drugs that seem to have the highest incidence of osteochemionecrosis are: zoledronate, pamidronate, alendronate, risendronate and ibandronate, from the greatest to the least. Additionally, the risk of osteonecrosis being produced is accumulative and may reach 21% in the third year of intravenous bisphosphonate use.

Osteochemonecrosis of the Jaws due to Bisphosphonate Treatments. Update

Bisphosphonates (BP),were initially used in industry and later as a drug due to their great affinity to osseous tissue, because of their powerful antiresorptive effect as a treatment in various osteopathies, such as osteoporosis, Paget disease or hypercalcemia associated with some malignant tumors, as myeloma or breast cancer.They are administered orally or intravenously, and although well tolerated, the most frequent side effects are gastrointestinal, in addition to osteonecrosis when they are administered via endovenous. The aim of this work has been to evaluate the existing publications in accredited scientific literature on biphosphonatesand their action mechanism and the relationship with the appearance of osteonecrosis of the jaws. Although the mechanism by which osteonecrosis of the jaws develops is not known exactly, there seems to be influence by osteoclast inhibiton, antiangiogenic action, an inhibitory effect on the cellular cycle by the keratinocytes, as well as, reinforcement of the chemiotoxic action in oncological patients treated with other drugs. Clinically, it ranges from a non-specificity of symptoms to lesions such as osteomyelitis with necrosis and osseous sequesters that may be accompanied by fetor ex oris, with the appearance of many Actinomyces contaminated lesions.As for published antecedents on osteonecrosis due to bisphosphonate treatment found until 2006: 46.5% had a previous diagnosis of multiple myeloma; 38.8% were patients with metastatic breast cancer; 6.2% patients of metastatic prostate cancer; 4.1% suffered from osteoporosis; 3.5% from other metastatic diseases and 0.8% had Paget disease. The drugs that seem to have the highest incidence of osteochemionecrosis are: zoledronate, pamidronate, alendronate, risendronate and ibandronate, from the greatest to the least.Additionally, the risk of osteonecrosis being produced is accumulative and may reach 21% in the third year of intravenous bisphosphonate use (AU)

No disponible

Grado de aceptación y utilidad de un boletín terapéutico en la práctica farmacéutica / Degree acceptance and utility of a pharcotherapeutic bulletin in pharmaceutical practise

Introducción: Sendagaiak es un boletín terapéutico elaborado por los CIM de los COF de Euskadi. Los diferentes números incluyen varios tipos de artículos: monografías de medicamentos, revisiones de patologías, notas informativas, revisiones de grupos terapéuticos, artículos sobre conocimientos generales y fichas de principios activos. Para evaluar la satisfacción y utilidad práctica de Sendagaiak en la práctica farmacéutica, hemos realizado un estudio transversal entre los lectores. Métodos: junto con el ejemplar de noviembre-diciembre de 2000 se remitió una encuesta y un sobre-respuesta. Se admitieron encuestas hasta abril de 2001. Los resultados fueron procesados con Microsoft Access® y Excel(R). Resultados: Se recibieron 218 respuestas. Leen habitualmente Sendagaiak 90,8% y sólo a veces 9,2%. 78,4% encontraron artículos interesantes en casi todos los números, 13,8% en la mitad y 7,8% en ocasiones. La aceptación de los distintos tipos de artículos es similar. El formato es bueno o muy bueno para el 89,9% y regular para el resto. El lenguaje utilizado es claro y asequible para todos. Todas las respuestas califican a Sendagaiak bastante o muy interesante. En el último año Sendagaiak ha resultado útil para resolver un problema concreto para el 88,6% de los farmacéuticos. Discusión: Sendagaiak es una publicación bien adaptada a las necesidades de la práctica farmacéutica, puesto que en la mayoría de los números se encuentran artículos interesantes, habitualmente permite resolver problemas y su formato y lenguaje son adecuados. La favorable aceptación del boletín y la similar valoración de los diversos tipos de artículos indican que Sendagaiak satisface los diferentes requerimientos profesionales de los lectores (AU)

No disponible